contusugene ladenovec

Drug Overview

Contusugene ladenovec is an investigational gene therapy agent developed for use in oncology. It is not a conventional chemotherapy drug or biological antibody. Instead, it is a viral vector-based gene therapy designed to restore the function of a critical tumor-suppressing gene that is lost or damaged in many human cancers. This places contusugene ladenovec within the category of targeted therapy and gene-based cancer treatment, making it a scientifically significant agent in the evolution of precision oncology.

Developed by Introgen Therapeutics, it carries a functional copy of the p53 tumor suppressor gene and delivers it directly into tumor cells using a modified adenoviral vector. The goal is to reinstate the cell’s natural ability to detect damage and initiate controlled cell death, a function compromised in the majority of human cancers.

• Generic Name: Contusugene ladenovec
• US Brand Names: Advexin (used during clinical development; not commercially available)
• Drug Class: Gene Therapy Agent; Adenoviral Vector-Based p53 Tumor Suppressor Gene Delivery System; Targeted Oncology Therapy
• Route of Administration: Intratumoral injection or intravenous infusion, depending on clinical protocol
• FDA Approval Status: Not FDA-approved in the United States. Approved in China under the name Gendicine, making it one of the first gene therapy products approved anywhere in the world for cancer treatment

What Is It and How Does It Work? (Mechanism of Action)

Contusugene ladenovec works through a gene replacement strategy targeting one of the most fundamental defects in human cancer, the loss of functional p53 protein activity. The p53 protein, encoded by the TP53 gene, is often called the guardian of the genome. Under normal conditions, p53 monitors cellular DNA health and, when damage is detected, triggers cell cycle arrest, DNA repair, or apoptosis. The TP53 gene is mutated or inactivated in a large proportion of human cancers, removing this protective checkpoint and allowing tumors to grow without restraint.

Contusugene ladenovec uses a modified, replication-deficient adenovirus as a delivery vehicle. This vector cannot cause infection but retains its natural ability to enter human cells efficiently. It carries a fully functional, wild-type copy of the TP53 gene inside. Upon administration, the adenoviral vector binds to the coxsackievirus and adenovirus receptor (CAR) on tumor cell surfaces and enters through receptor-mediated endocytosis. Once inside the nucleus, the functional TP53 gene is expressed, producing normal p53 protein. This restored p53 reactivates the apoptosis pathway, halts the cell cycle at the G1 checkpoint through upregulation of p21, and sensitizes tumor cells to radiation and chemotherapy. The therapy essentially re-arms cancer cells with the self-destruction mechanism they had lost.

FDA Approved Clinical Indications

Contusugene ladenovec does not hold FDA approval for any indication. In China, it is approved under the name Gendicine for head and neck squamous cell carcinoma in combination with radiotherapy. All indications in Western markets remain investigational.

Oncological Uses (Approved in China / Investigational in the US and Europe):

• Head and neck squamous cell carcinoma, the primary studied tumor type, administered alongside radiotherapy
• Non-small cell lung cancer, evaluated in early-phase studies
• Bladder cancer, investigated via intratumoral delivery approaches
• Breast cancer, studied in combination with chemotherapy
• Ovarian cancer, explored with platinum-based chemotherapy
• Hepatocellular carcinoma, studied as part of combination locoregional treatment

Non-Oncological Uses:

• There are no known non-oncological indications under active investigation at this time

Dosage and Administration Protocols

All dosing is protocol-driven, as no standardized prescribing information exists for routine clinical use outside of China. Parameters below are drawn from published clinical trial data and the Chinese approved prescribing framework.

Clinical Efficacy and Research Results

The most substantial evidence base for contusugene ladenovec is concentrated in head and neck squamous cell carcinoma. Pivotal data supporting its Chinese approval demonstrated that patients receiving this agent alongside radiotherapy achieved meaningfully higher rates of complete and partial tumor response compared to radiotherapy alone, representing a landmark outcome for gene therapy in oncology.

Research between 2020 and 2025 has continued to expand the evidence base across broader solid tumor settings. Combination studies in hepatocellular carcinoma and lung cancer have reported tumor stabilization and objective response signals in subsets of treated patients. A consistent finding across multiple studies is that contusugene ladenovec enhances tumor sensitivity to radiation and chemotherapy, producing better responses in combination than either treatment achieves alone. Biomarker research is now a central focus, with investigators examining whether tumors with confirmed TP53 mutations or complete loss of p53 expression are most likely to respond. Larger randomized controlled trials meeting Western regulatory standards remain a priority for advancing this agent toward potential FDA reconsideration.

Safety Profile and Side Effects

Contusugene ladenovec does not carry an FDA-issued Black Box Warning. Based on clinical trial data and post-marketing safety information from China, the agent has demonstrated a generally manageable safety profile. The most consistently reported effects are related to the immune system’s response to the adenoviral vector rather than direct drug toxicity.

Common Side Effects (greater than 10%):

• Self-limiting fever, the most frequently reported adverse event, typically occurring within 24 to 48 hours of each injection
• Chills and flu-like symptoms accompanying fever episodes, consistent with an immune response to the viral vector
• Mild to moderate injection site pain and localized swelling
• Fatigue, commonly reported and often compounded by concurrent radiotherapy or chemotherapy
• Mild elevation of inflammatory markers following administration

Serious Adverse Events:

• Severe systemic inflammatory response in rare cases, requiring medical management and potential treatment interruption
• Serious infusion-related reactions during intravenous administration, including hypotension and respiratory changes
• Transient liver enzyme elevations, particularly in patients receiving intravenous formulations
• Secondary infections at intratumoral injection sites in a small number of patients

Management Strategies:

Fever and flu-like reactions should be managed with acetaminophen or non-steroidal anti-inflammatory drugs and do not typically require treatment discontinuation. Injection site reactions can be addressed with standard wound care. Liver function must be monitored before and throughout treatment. Any signs of systemic inflammatory response should be managed immediately with supportive care. Pre-medication with antipyretics before each session may reduce fever severity.

Research Areas

Contusugene ladenovec sits at an important intersection of gene therapy, immunotherapy, and emerging precision oncology research. Investigators are actively exploring its combination with immune checkpoint inhibitors, particularly PD-1 and PD-L1 inhibitors. The rationale is compelling: restored p53 function increases the immunogenicity of dying tumor cells, potentially making them more visible to the immune system and more responsive to checkpoint blockade. Researchers are also investigating improved vector delivery systems, including nanoparticle-encapsulated TP53 constructs, as next-generation alternatives to adenoviral delivery that may reduce immune-mediated side effects. Emerging interest in combining p53 restoration with CRISPR-based gene editing tools represents a frontier area bridging gene therapy with precision molecular medicine.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

• Complete blood count to assess baseline immune and hematological status
• Comprehensive liver function panel including ALT, AST, and total bilirubin
• Renal function tests including serum creatinine and estimated glomerular filtration rate
• Baseline imaging with CT or PET scan to document tumor location and accessibility
• Coagulation studies prior to intratumoral injection to reduce procedural bleeding risk
• Serum pregnancy test for all women of childbearing potential
• Molecular tumor profiling to assess TP53 mutation status where available

Precautions During Treatment:

• Patients should be monitored for fever and systemic reactions for a minimum of two hours following each administration session
• Intratumoral injections must be performed only by trained physicians using appropriate imaging guidance
• Concurrent radiotherapy schedules must be carefully coordinated with gene therapy administration
• Liver function must be reassessed before each treatment cycle
• Biosafety precautions appropriate for viral vector handling must be observed by all clinical staff

Do’s and Don’ts:

• Inform your oncologist about every medication, supplement, and herbal product you are currently taking
• Attend every scheduled treatment session, laboratory test, and follow-up imaging appointment
• Report any fever above 38.5 degrees Celsius, breathing difficulty, or unusual swelling at the injection site immediately
• Rest adequately in the 24 hours following each treatment session as flu-like symptoms are common and temporary
• Do not take immunosuppressive medications without explicit oncologist approval
• Do not skip liver function blood tests between cycles as these results directly inform dosing decisions
• Do not use contusugene ladenovec outside of an approved clinical trial or authorized treatment center

Legal Disclaimer

The information presented in this guide is intended solely for educational and informational purposes and does not constitute medical advice, a clinical diagnosis, or a formal treatment recommendation. Contusugene ladenovec is not approved by the United States Food and Drug Administration or the European Medicines Agency for any oncological indication. It is approved in China under the trade name Gendicine for head and neck squamous cell carcinoma in combination with radiotherapy. Access to this agent in Western markets is available only through participation in formally approved clinical trials. All treatment decisions must be made exclusively by a qualified and licensed oncologist or healthcare professional in full consideration of the patient’s medical history, current clinical status, and the regulatory framework of their country of residence. This content must not be used in place of direct professional medical consultation.